Epidemiological comparison of the first and second waves of the COVID-19 pandemic in Nigeria, February 2020-April 2021.


Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
11 2021
Historique:
received: 03 08 2021
accepted: 24 10 2021
entrez: 19 11 2021
pubmed: 20 11 2021
medline: 24 11 2021
Statut: ppublish

Résumé

With reports of surges in COVID-19 case numbers across over 50 countries, country-level epidemiological analysis is required to inform context-appropriate response strategies for containment and mitigation of the outbreak. We aimed to compare the epidemiological features of the first and second waves of COVID-19 in Nigeria. We conducted a retrospective analysis of the Surveillance Outbreak Response Management and Analysis System data of the first and second epidemiological waves, which were between 27 February and 24 October 2020, and 25 October 2020 to 3 April 2021, respectively. Descriptive statistical measures including frequencies and percentages, test positivity rate (TPR), cumulative incidence (CI) and case fatality rates (CFRs) were compared. A p value of <0.05 was considered statistically significant. All statistical analyses were carried out in STATA V.13. There were 802 143 tests recorded during the study period (362 550 and 439 593 in the first and second waves, respectively). Of these, 66 121 (18.2%) and 91 644 (20.8%) tested positive in the first and second waves, respectively. There was a 21.3% increase in the number of tests conducted in the second wave with TPR increasing by 14.3%. CI during the first and second waves were 30.3/100 000 and 42.0/100 000 respectively. During the second wave, confirmed COVID-19 cases increased among females and people 30 years old or younger and decreased among urban residents and individuals with travel history within 14 days of sample collection (p value <0.001). Most confirmed cases were asymptomatic at diagnosis during both waves: 74.9% in the first wave; 79.7% in the second wave. CFR decreased during the second wave (0.7%) compared with the first wave (1.8%). Nigeria experienced a larger but less severe second wave of COVID-19. Continued implementation of public health and social measures is needed to mitigate the resurgence of another wave.

Sections du résumé

BACKGROUND
With reports of surges in COVID-19 case numbers across over 50 countries, country-level epidemiological analysis is required to inform context-appropriate response strategies for containment and mitigation of the outbreak. We aimed to compare the epidemiological features of the first and second waves of COVID-19 in Nigeria.
METHODS
We conducted a retrospective analysis of the Surveillance Outbreak Response Management and Analysis System data of the first and second epidemiological waves, which were between 27 February and 24 October 2020, and 25 October 2020 to 3 April 2021, respectively. Descriptive statistical measures including frequencies and percentages, test positivity rate (TPR), cumulative incidence (CI) and case fatality rates (CFRs) were compared. A p value of <0.05 was considered statistically significant. All statistical analyses were carried out in STATA V.13.
RESULTS
There were 802 143 tests recorded during the study period (362 550 and 439 593 in the first and second waves, respectively). Of these, 66 121 (18.2%) and 91 644 (20.8%) tested positive in the first and second waves, respectively. There was a 21.3% increase in the number of tests conducted in the second wave with TPR increasing by 14.3%. CI during the first and second waves were 30.3/100 000 and 42.0/100 000 respectively. During the second wave, confirmed COVID-19 cases increased among females and people 30 years old or younger and decreased among urban residents and individuals with travel history within 14 days of sample collection (p value <0.001). Most confirmed cases were asymptomatic at diagnosis during both waves: 74.9% in the first wave; 79.7% in the second wave. CFR decreased during the second wave (0.7%) compared with the first wave (1.8%).
CONCLUSION
Nigeria experienced a larger but less severe second wave of COVID-19. Continued implementation of public health and social measures is needed to mitigate the resurgence of another wave.

Identifiants

pubmed: 34794956
pii: bmjgh-2021-007076
doi: 10.1136/bmjgh-2021-007076
pmc: PMC8602923
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Lancet Infect Dis. 2021 Jul;21(7):922-923
pubmed: 34174236
Am J Trop Med Hyg. 2020 Dec;103(6):2376-2381
pubmed: 33124545
Int J Infect Dis. 2021 Mar;104:742-745
pubmed: 33556610
Pan Afr Med J. 2020 Dec 15;37(Suppl 1):47
pubmed: 33552375
J Infect. 2021 Apr;82(4):84-123
pubmed: 33152376
Int J Infect Dis. 2021 Apr;105:374-376
pubmed: 33684560
Health Secur. 2021 Mar-Apr;19(2):223-228
pubmed: 33346721
Lancet. 2021 Apr 3;397(10281):1265-1275
pubmed: 33773118
BMJ Open. 2020 Dec 17;10(12):e044079
pubmed: 33334842
J Infect. 2021 Jun;82(6):e14-e15
pubmed: 33826927
Am J Trop Med Hyg. 2021 Jan 20;104(3):1034-1040
pubmed: 33534753
BMJ. 2020 Aug 27;370:m3350
pubmed: 32855153
Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27285-27291
pubmed: 33060298
Epidemiol Infect. 2020 Sep 11;148:e208
pubmed: 32912370
PLoS One. 2021 Mar 15;16(3):e0248281
pubmed: 33720975
BMJ Glob Health. 2021 Mar;6(3):
pubmed: 33741561
Chaos. 2021 Mar;31(3):031105
pubmed: 33810707
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
CMAJ. 2012 Aug 7;184(11):1265-9
pubmed: 22371511
BMC Public Health. 2020 Nov 19;20(1):1742
pubmed: 33213391
J Glob Health. 2020 Dec;10(2):020399
pubmed: 33274062

Auteurs

Oluwatosin Wuraola Akande (OW)

Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria akande.wuraola@gmail.com.
Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.

Kelly Osezele Elimian (KO)

Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Department of Global Public Health, Karolinska Institute, Stockholm, Sweden.

Ehimario Igumbor (E)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
School of Public Health, University of the Western Cape, Bellville, South Africa.

Lauryn Dunkwu (L)

Tony Blair Institute for Global Change, Abuja, Federal Capital Territory, Nigeria.

Chijioke Kaduru (C)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
IQVIA, Abuja, Nigeria.

Olubunmi Omowunmi Olopha (OO)

Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.

Dabri Olohije Ohanu (DO)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Lilian Nwozor (L)

Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.

Emmanuel Agogo (E)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Resolve to Save Lives, Abuja, Federal Capital Territory, Nigeria.

Olusola Aruna (O)

International Health Regulations (IHR) Strengthening Project, Global Operations, UK Health Security Agency, London, UK.

Muhammad Shakir Balogun (MS)

African Field Epidemiology Network, Abuja, Federal Capital Territory, Nigeria.

Olaolu Aderinola (O)

Health Emergency Preparedness and Response, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Anthony Ahumibe (A)

Public Health Laboratory Services, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Chinedu Arinze (C)

Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Sikiru Olanrewaju Badaru (SO)

Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

William Nwachukwu (W)

Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Augustine Olajide Dada (AO)

African Field Epidemiology Network, Abuja, Federal Capital Territory, Nigeria.

Cyril Erameh (C)

Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Khadeejah Hamza (K)

Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria.

Tarik Benjamin Mohammed (TB)

Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Nnaemeka Ndodo (N)

Public Health Laboratory Services, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Celestina Obiekea (C)

Public Health Laboratory Services, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Chinenye Ofoegbunam (C)

Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Oladipo Ogunbode (O)

Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Cornelius Ohonsi (C)

Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.

Ekaete Alice Tobin (EA)

Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Rimamdeyati Yashe (R)

Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Afolabi Adekaiyaoja (A)

Tony Blair Institute for Global Change, Abuja, Federal Capital Territory, Nigeria.

Michael C Asuzu (MC)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Department of Community Medicine, University College Hospital, Ibadan, Oyo State, Nigeria.

Rosemary Ajuma Audu (RA)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Department of Microbiology, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.

Muhammad Bashir Bello (MB)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Center for Advanced Medical Research and Training, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria.

Shaibu Oricha Bello (SO)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Department of Pharmacology & Therapeutics, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria.

Yusuf Yahaya Deeni (YY)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Department of Microbiology & Biotechnology, Federal University Dutse, Dutse, Jigawa State, Nigeria.
Centre for Environmental and Public Health Research and Development, Kano, Kano State, Nigeria.

Yahya Disu (Y)

Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Gbenga Joseph (G)

Health Emergency Preparedness and Response, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Chidiebere Ezeokafor (C)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
National Agency for the Control of AIDS, Abuja, Federal Capital Territory, Nigeria.

Zaiyad Garba Habib (ZG)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
University of Abuja Teaching Hospital, Gwagwalada, Abuja, Federal Capital Territory, Nigeria.

Christian Ibeh (C)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Department of Community Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria.

Ifeanyi Franklin Ike (IF)

eHealth Africa, Abuja, Federal Capital Territory, Nigeria.

Emem Iwara (E)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Maryland Global Initiatives Corporation, Abuja, Federal Capital Territory, Nigeria.

Rejoice Kudirat Luka-Lawal (RK)

Health Emergency Preparedness and Response, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Geoffrey Namara (G)

World Health Organization, Abuja, Federal Capital Territory, Nigeria.

Tochi Okwor (T)

Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.

Lois Olajide (L)

Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Oluwafunke Olufemi Ilesanmi (OO)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
World Health Organization, Abuja, Federal Capital Territory, Nigeria.

Solomon Omonigho (S)

Department of Microbiology, University of Benin, Benin, Edo State, Nigeria.

Ferdinand Oyiri (F)

Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Koubagnine Takpa (K)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Joint United Nations Programme on AIDS (UNAIDS), Abuja, Federal Capital Territory, Nigeria.

Nkem Usha Ugbogulu (NU)

Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Priscilla Ibekwe (P)

Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

John Oladejo (J)

Health Emergency Preparedness and Response, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Elsie Ilori (E)

Surveillance and Epidemiology, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Chinwe Lucia Ochu (CL)

Prevention Programmes & Knowledge Management, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.
Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.

Chikwe Ihekweazu (C)

Nigeria COVID-19 Research Coalition, Abuja, Federal Capital Territory, Nigeria.
Office of the Director General, Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH